Paclitaxel Viatris 30 mg, 100 mg, 300 mg Concentrate for dilution for infusion.
PDF Leaflet Revision Date: 27 April 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Palliative treatment of advanced cancers including ovarian, breast, and non-small cell lung cancer.
Dosage (summary)
175 mg/mu00b2 IV over 3 hours every 3 weeks; adjust for neutrophil counts.
Special Populations
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Contraindicated in pregnancy; unknown if excreted in breast milk.
Key Drug Interactions
- Cisplatin
- Ketoconazole
- Doxorubicin
Contraindications
- Severe hypersensitivity to paclitaxel
- Neutrophils < 1500/mmu00b3
Common side effects
- Neutropenia
- Peripheral neuropathy
- Hypersensitivity reactions
- Nausea
- Vomiting
Counselling Points
- Premedicate with corticosteroids and antihistamines
- Monitor for hypersensitivity
- Avoid pregnancy during treatment
Serious warnings
- Severe hypersensitivity reactions
- Bone marrow suppression
- Cardiovascular events
Important Disclaimer
The Paclitaxel Viatris 30 mg, 100 mg, 300 mg Concentrate for dilution for infusion. professional information leaflet below is the property of Viatris South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
